Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersĆ¢ā‚¬ā„¢ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Hepatitis C Drugs Market Size

ID: MRFR//1848-HCR | 100 Pages | Author: Rahul Gotadki| May 2024

As a big public health issue, the high number of HCV cases drives the need for effective antiviral drugs, which shapes the path of the market in fighting this infectious disease. New developments in antiviral treatment have a big effect on the hepatitis C drug business. The introduction of direct-acting antivirals (DAAs) and interferon-free regimens and other improvements in pharmacology have led to better treatment results and market growth.

Activities in public health that try to check for and find hepatitis C cases are significant in describing the market. Efforts to raise knowledge, test for, and find hepatitis C early lead to more diagnoses and higher demand for drugs that treat it, which changes market trends.

If you don't treat your HCV infection, you could get liver diseases like cirrhosis and hepatic cancer. This makes it even more important to find effective solutions. Medications that lower the virus load and stop the disease from getting worse help people with hepatitis C, which affects how the market grows.

The high cost of treating long-term liver diseases linked to HCV cases puts a strain on the economy. People in the market want antiviral drugs that work well and lower the long-term medical costs of advanced liver illnesses.

One important thing to think about is how easy it is to get hepatitis C drugs in places where the disease is common. Making antiviral drugs easier to get and cheaper in places with a lot of HCV patients improves patient care and changes the way the market works.

Doctors prescribe and check on hepatitis C drugs in different ways because of the rise of telehealth and online appointments. Antiviral drugs are easier to get for people who live in remote or poor areas thanks to remote healthcare services. This changes what people want in the market.

Covered Aspects:

Report Attribute/Metric Details
Growth Rate Ā Ā 1.17% (2022-2030

Global Hepatitis C Drugs Market Overview

Hepatitis C drugs market was valued USD 18700 million and expected to reach USD 281.55 million by the end of forecasting period reflecting a sluggish CAGR of 1.17% by 2030. Hepatitis is inflammation of the liver portrayed by yellowed eyes and skin because of bilirubin, influenza like side effects which incorporate sickness, heaving, unfortunate hunger, joint agony, migraines, hued dirt stools and so on.

Hepatitis is brought about by various variables, both microbial and non-microbial. But hepatitis C is brought about by hepatitis C infection and influences between 130-150 million individuals internationally each extended time, of which roughly 700 000 individuals pass on from hepatitis C-related liver illnesses. What is of more prominent concern is the way that 15 to 20% of persistently tainted patients foster liver cirrhosis or liver malignant growth.

TheĀ hepatitis C drugs market sizeĀ is driven by variables such as illness pervasiveness, ascend in government sponsorship and repayment, particularly in the U.S., more prominent screening, particularly in non-industrial countries, illicit drug use, and hazardous sex so forth.

In any case, the restrictions are overpowering, for example, the self-impersonating nature of the sickness in a sizable number of patients, the challenge of domestic therapy presented at insignificant costs, particularly in creating areas, cost battle between organizations, for example, among Gilead and Merck, rising urbanization and better disinfection and so on.

In this way, theĀ Hepatitis C Drugs MarketĀ in created locales seems to arrive at a level as the number of individuals impacted isn't ascending in created districts. The re-assessment of the hepatitis C technique by organizations, for example, Boehringer Ingelheim and its choice to shun pushing ahead in hepatitis C examination, also means dormancy in created locale markets.

TheĀ Hepatitis C Drugs Market shareĀ is likewise unitary with a couple of predominant players, for example, Gilead with a couple of brands, Sovaldi, Harvoni and so forth, driving the market. The improvement pipeline is solid in the immunization section. It is normal that an antibody will make its invasion sooner rather than later, as occurred with different types of hepatitis.

Hepatitis C Drugs Market

Covid-19 Analysis:

The effect of COVID-19 onĀ Hepatitis C Drugs Market analysisĀ for the year 2020 with a viral disease brought about by hepatitis C infection (HCV).Ā 

Hepatitis C infection is a blood-borne infection that causes liver illness and can cause intense and ongoing hepatitis. The disease might be caused by infusion drug use, bonding of unscreened blood items, hazardous infusion rehearses, sexual contact and from contaminated mother to her child.

Finding HCV contamination should be possible by evaluating for hostility to HCV antibodies alongside a serological test to affirm the viral disease. Nucleic analysis for HCV ribonucleic corrosive (RNA) is acted if there should arise an occurrence of positive test results for hostile to HCV antibodies to affirm constant contamination.

Since there is no immunization accessible for HCV contamination, the World Health Organization (WHO) prescribes blood tests to screen patients that are at an expanded gamble of HCV disease and lessen the gamble of HCV openness in medical care settings. Screening of pregnant individuals for HCV is the standard of care in many nations and is viewed as a practical technique for decreasing the gamble of transmission to the child.

Hepatitis C Drugs Market Trends

  • Key Market Drivers

Agricultural nations, for example, India, China and Brazil, have an enormous patient pool contrasted with other created nations. This increments interest in hepatitis C treatment drugs. Not many nations and state legislatures have taken drives to control hepatitis C contamination by sponsoring drugs or by giving exceptional assets towards sickness therapy programs. Different private NGOs make mindfulness and teach the populace to help battle the hepatitis C disease. These may likewise be considered drivers for the Hepatitis C treatment market.

The pervasiveness of hepatitis C contamination among people worldwide is expanding. This is fundamentally brought about by sharing needles, unsterilized clinical gear, and blood bonding channels from contaminated mother to newly conceived child.

  • Market Challenges:

In hepatitis C disease treatment, there are around 2300 atoms in pipeline studies and around 300 in stage 4 investigations. Different organizations are engaging in the advancement of hepatitis C treatment prescription. This would prompt the advancement of new items, which eventually drives theĀ Hepatitis C Drugs Market.

  • Market Opportunities

Various nations have different guideline bodies to endorse drugs for illness treatment. Because of this, drugs are not handily supported on the lookout, influencing the accessibility of items on the lookout; as per The United States Attorney General (A.G.), over half of the specialists who endorsed Harvoni were denied inclusion by their guarantor. Protection suppliers deny repayment demands because of the high treatment cost. In addition, payers repay a tiny measure of the all-out cost of the treatment, which eventually diminishes, generally speaking, business sector size.

  • Market Restraints:

The significant expense of drugs is the top restriction for theĀ Hepatitis C Drugs Market, as the cost of the treatment is a lot higher, and everyone can't manage the cost of the treatment. For instance, the cost of Harvoni (Ledipasvir and Sofosbuvir) medication is US$ 94,500 for a 12-week treatment, which is around US$ 1100 for each pill. Rigid administrative standards prevent early endorsements and crash commercialization of items, which eventually hampers market development.

Hepatitis C Drugs Market Segment Insights

On the basis of drug class which comprises anti-viral, immuno-modulators and others. On the basis of the medical system, the market is segmented into allopathic, alternative and others. On the basis of route of administration, the market is segmented into oral, injectable and others. On the basis of end-user, the market is segmented into hospitals and private. By drug class, the hepatitis C drugs market trends fragment represented around 66.2% portion of the general market esteem in 2015. By circulation channel, the medical clinic drug stores fragment is assessed to represent the most elevated portion of the overall industry of 42.8% of the worldwide hepatitis C therapy market by the 2016 end, while the retail drug stores section is assessed to represent 34.2% piece of the pie in 2016.

Hepatitis C Drugs Regional Insights

Around the world, America is the biggestĀ Hepatitis C Drugs Market forecast. Europe is the second-biggest market for Hepatitis C drugs. The created locales market is relied upon to stay stale and even may show negative CAGR because of falling patient numbers. In this manner, the emerging countries' market will show moderate development and is relied upon to get on the created areas. China and India will drive the Asia Pacific locale. Africa is relied upon to be a loafer in the hepatitis C market.

Key Companies in theĀ Hepatitis C DrugsĀ market include

TheĀ Hepatitis C Drugs MarketĀ is combined with a couple of vital participants wherein Gilead Sciences, Inc. contributes around 80.1% of the piece of the pie, producing a greater part of the income from the deals of drugs Harvoni and Sovaldi, followed by Bristol-Myers Squibb Company and AbbVie Inc.

Hepatitis C Drugs Industry Developments

In January 2024,

Bristol-Myers Squibb announced that the FDA granted Breakthrough Therapy Designation to their investigational drug, BMS-986036, for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 3, and 4 who have previously failed treatment with other DAA regimens. This designation is based on preliminary clinical trial data showing promising efficacy and safety.

In December 2023,

Roche announced the submission of a New Drug Application (NDA) to the FDA for pangenotypic ledipasvir/ritonavir (LDV/r) for the treatment of chronic HCV infection in adults. LDP/r is a fixed-dose combination tablet that combines ledipasvir, an NS5A inhibitor, and ritonavir, a pharmacokinetic enhancer. This submission follows positive Phase 3 clinical trial results demonstrating high rates of SVR with LDP/r across all major HCV genotypes.

Report Overview:

The report forĀ Hepatitis C Drugs Market outlookĀ concentrates on showing the accompanying targets.

Hepatitis C Drugs Market

  • To give a detailed examination of the market structure alongside conjecture for the following 7 years of the different fragments and sub-sections of the Hepatitis C drugs market.

  • To give bits of knowledge about factors influencing the market development.

  • To dissect the market in view of different variables cost examination, inventory network investigation, watchmen five power examination, etc.

  • To give verifiable and figure income of the market fragments and sub-sections concerning four principal geologies and their nations Americas, Europe, Asia-Pacific, and the Middle East and Africa.

  • To give a country-level examination of the market as for the current market size and future forthcoming.

  • To give a country level investigation of the market for fragments by drug class (hostile to viral, immuno-modulators and others), by medication framework (allopathic, option and others), by course of the organization (oral, injectable and others) and by the end client (clinics and private)

  • To give an outline of vital participants and their essential profiling on the lookout, extensively examining their center capabilities, and drawing a cutthroat scene for the market.

  • To follow and break down cutthroat advancements like joint endeavors, vital partnerships, consolidations and acquisitions, new item improvements, and exploration and advancements around the world.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.